Compare HOG & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | PGEN |
|---|---|---|
| Founded | 1903 | 1998 |
| Country | United States | United States |
| Employees | 6400 | 47 |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1994 | 2013 |
| Metric | HOG | PGEN |
|---|---|---|
| Price | $24.74 | $7.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $24.00 | $8.33 |
| AVG Volume (30 Days) | 1.5M | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.97 | 0.03 |
| Revenue | ★ $4,473,175,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $3.79 | $81.04 |
| P/E Ratio | ★ $26.28 | $258.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.09 | $2.99 |
| 52 Week High | $29.22 | $8.27 |
| Indicator | HOG | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 62.16 |
| Support Level | $24.09 | $6.57 |
| Resistance Level | $24.68 | N/A |
| Average True Range (ATR) | 0.85 | 0.38 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 2.17 | 72.83 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model, into electric with the LiveWire brand, and is returning to smaller-displacement bikes with the Sprint. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.